Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 295, Issue 1, 2008, Pages

  Chmura, Kathryn ^a   Bai, Xiyuan ^a   Nakamura, Mari ^a   Kandasamy, Pitchaimani ^a   McGibney, Mischa ^a   Kuronuma, Koji ^a,d   Mitsuzawa, Hiroki ^a,d   Voelker, Dennis R ^a,b   Chan, Edward D ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokines; Gene regulation; Mollicutes; Toll like receptors

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MOXIFLOXACIN; RNA; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR AP 1; ANTIINFECTIVE AGENT; IL8 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; TLR2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BACTERIAL MEMBRANE; CONTROLLED STUDY; DRUG INHIBITION; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MYCOPLASMA PNEUMONIAE; NORTHERN BLOTTING; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ASTHMA; BIOSYNTHESIS; BRONCHUS; CELL MEMBRANE; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MYCOPLASMA PNEUMONIA;

ANTI-BACTERIAL AGENTS; ASTHMA; BRONCHI; CELL MEMBRANE; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-8; MAP KINASE SIGNALING SYSTEM; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; TOLL-LIKE RECEPTOR 2; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49049099273     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.90204.2008     Document Type: Article

References (81)

1. Abe S, Nakamura H, Inoue S, Takeda H, Saito H, Kato S, Mukaida N, Matsushima K, Tomoike H. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 22: 51-60, 2000.
2. ARF tumor suppressor gene. Oncogene 24: 2298-2306, 2005.
3. Araujo FG, Slifer TL, Remington JS. Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin Microbiol Infect 8: 26-30, 2002.
4. Baum SG. Mycoplasma Pneumoniae and Atypical Pneumonia. New York: Churchill Livingstone, 2000.
5. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlow AJ, Pavord ID. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 354: 697-708, 2006.
6. Beuther DA, Martin RJ. Antibiotics in asthma. Curr Allergy Asthma Rep 4: 132-138, 2004.
7. Bohnet S, Kotschau U, Braun J, Dalhoff K. Role of interleukin-8 in community-acquired pneumonia: relation to microbial load and pulmonary infection. Infection 25: 95-100, 1997.
8. Broaders SA, Hooper WC, Phillips DJ, Talkington DF. Mycoplasma pneumoniae subtype-independent induction of proinflammatory cytokines in THP-1 cells. Microb Pathog 40: 286-292, 2006.
9. Chan ED, Kalayanamit T, Lynch DA, Tuder R, Arndt P, Winn R, Schwarz MI. Mycoplasma pneumoniae-associated bronchiolitis causing severe restrictive lung disease in adults. Chest 115: 1188-1194, 1999.
10. Chan ED, Morris KR, Belisle JT, Hill P, Remigio LK, Brennan PJ, Riches DWH. Induction of inducible nitric oxide synthase-NO by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK, MKK7-JNK, and NF-κB signaling pathways. Infect Immun 69: 2001-2010, 2001.
11. Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia. West J Med 162: 133-142, 1995.
12. Chan ED, Winston BW, Jarpe MB, Wynes MW, Riches DWH. Preferential activation of the p46 isoform of JNK/SAPK in mouse macrophages by TNF-α. Proc Natl Acad Sci USA 94: 13169-13174, 1997.
13. Chiba H, Pattanajitvilai S, Evans AJ, Harbeck RJ, Voelker DR. Human surfactant protein D (SP-D) binds Mycoplasma pneumoniae by high affinity interactions with lipids. J Biol Chem 277: 20379-20385, 2002.
14. Chu HW, Jeyaseelan S, Rino JG, Voelker DR, Wexler RB, Campbell K, Harbeck RJ, Martin RJ. TLR2 signaling is critical for Mycoplasma pneumoniae-induced airway mucin expression. J Immunol 174: 5713-5719, 2005.
15. Fonseca-Aten M, Rios AM, Mejias A, Chavez-Bueno S, Katz K, Gomez AM, McCracken GH, Hardy RD. Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice. Am J Respir Cell Mol Biol 32: 201-210, 2005.
16. Gabridge MG, Singer SE, Esposito RA. Gradient, polyacrylamide gel electrophoresis of proteins from cytotoxic mycoplasma membranes. Biochem Biophys Res Commun 70: 271-279, 1976.
17. Gil JC, Cedillo RL, Mayagoitia BG, Paz MD. Isolation of Mycoplasma pneumoniae from asthmatic patients. Ann Allergy Asthma Immunol 70: 23-25, 1993.
18. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125: 52S-61S, 2004.
19. Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, Patel P, Duffy L, Cassell G, McCracken GH, Ramilo O. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic pro-file. Infect Immun 69: 3869-3876, 2001.
20. Hardy RD, Rios AM, Chavez-Bueno S, Jafri HS, Hatfield J, Rogers BB, McCracken GH, Ramilo O. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother 47: 1614-1620, 2003.
21. Hatipoglu U, Rubinstein I. Low-dose, long-term macrolide therapy in asthma: An overview [Online]. Clin Mol Allergy 2: 4, 2004.
22. Ichiyama T, Nishikawa M, Yoshitomi T, Hasegawa S, Matsubara T, Hayashi T, Furukawa S. Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45: 44-47, 2001.
23. Iizasa H, Matsushima KIL8. Cytokine Reference, vol. 1, Ligands, edited by Oppenheim JJ and Feldmann M. San Diego: Academic Press, 2001, p. 1061-1067.
24. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
25. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354: 1589-1600, 2006.
26. Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis? Am J Respir Crit Care Med 172: 1078-1089, 2005.
27. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, Tokue Y, Watanabe A, Nukiwa T. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 49: 745-755, 2002.
28. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 11: 13-18, 1999.
29. Kraft M. The role of bacterial infections in asthma. Clin Chest Med 21: 301-313, 2000.
30. Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion BP, Gaydos CA, Martn RJ. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 158: 998-1001, 1998.
31. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 121: 1782-1788, 2002.
32. Kudoh S, Uetake K, Hagiwara K, Hirayama M, Hus LH, Kimura H, Sugiyama Y. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Jpn J Thorac Dis: 632-642, 1987.
33. Kunsch C, Lang RK, Rosen CA, Shannon MF. Synergistic transcriptional activation of the IL-8 gene by NF-κB p65 (RelA) and NF-IL-6. J Immunol 153: 153-164, 1994.
34. Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 59: 793-805, 2004.
35. Lieberman D, Lieberman D, Printz S, Ben-Yaakov M, Lazarovivh Z, Ohana B, Friedman MG, Dvoskin B, Leinonen M, Boldur I. Atypical pathogen infection in adults with acute exacerbation of bronchial asthma. Am J Respir Crit Care Med 167: 406-410, 2003.
36. Little FF. Treating acute asthma with antibiotics-not quite yet, editorial. N Engl J Med 354: 1632-1634, 2006.
37. Llibre JM, Urban A, Garcia E, Carrasco MA, Murcia C. Bronchiolitis obliterans organizing pneumonia associated with acute Mycoplasma pneumoniae infection. Clin Infect Dis 25: 1340-1342, 1997.
38. Martin RJ. Infections and asthma. Clin Chest Med 27: 87-98, 2006.
39. Martin RJ, Chu HW, Honour JM, Harbeck RJ. Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. Am J Respir Cell Mol Biol 24: 557-582, 2001.
40. McElhaney Membrane structure RN. Mycoplasmas: Molecular biology and pathogenesis, edited by Maniloff J, McElhaney RN, Finch LR and Baseman JB. Washington, D.C.: American Society for Microbiology, 1992, p. 113-155.
41. Morris KR, Lutz RD, Choi HS, Kamitani T, Chmura K, Chan ED. Role of the NF-κB signaling pathway and κB cis-regulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipoarabinomannan induction of nitric oxide. Infect Immun 71: 1442-1452, 2003.
42. Mu HH, Pennock ND, Humphreys J, Kirschning CJ, Cole BC. Engagement of Toll-like receptors by mycoplasmal superantigen: downregulation of TLR2 by MAM/TLR4 interaction. Cell Microbiol 7: 789-797, 2005.
43. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 284: L566-L577, 2003.
44. Mukaida N, Mahe Y, Matsushima K. Cooperative interaction of nuclear factor-κB- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 265: 21128-21133, 1990.
45. Narita M, Tanaka H, Togashi T, Abe S. Cytokines involved in CNS manifestations caused by Mycoplasma pneumoniae. Pediatr Neurol 33: 105-109, 2005.
46. Narita M, Tanaka H, Yamada S, Abe S, Ariga T, Sakiyama Y. Significant role of interleukin-8 in pathogenesis of pulmonary disease due to Mycoplasma pneumoniae infection. Clin Diagn Lab Immunol 8: 1028-1030, 2001.
47. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272: 21096-21103, 1997.
48. Powers C, Krutzsch H, Gardner K. Modulation of JunD-AP-1 DNA binding activity by AP-1-associated factor 1 (AF-1). J Biol Chem 271: 30089-30095, 1996.
49. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNγ-inducing factor) induces IL-8 and IL-1β via TNF-α production from non-CD14+ human blood mononuclear cells. J Clin Invest 101: 711-721, 1998.
50. Rawadi G, Roman-Roman S. Mycoplasma membrane lipoproteins induce proinflammatory cytokines by a mechanism distinct from that of lipopolysaccharide. Infect Immun 64: 637-643, 1996.
51. Razin Mycoplasmas S. Medical Microbiology, edited by Baron S. Galveston, TX: The University of Texas Medical Branch at Galveston, 1996, p. 475-485.
52. Richman-Eisenstat JBY, Jorens PG, Hebert CA, Ueki I, Nadel JA. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol Lung Cell Mol Physiol 264: L413-L418, 1993.
53. Roebuck KA. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res 19: 429-438, 1999.
54. Roger T, Out TA, Mukaida N, Matsushima K, Jansen HM, Lutter R. Enhanced AP-1 and NF-κB activities and stability of interleukin-8 (IL-8) transcripts are implicated in IL-8 mRNA superinduction in lung epithelial H292 cells. Biochem J 330: 429-435, 1998.
55. Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125: 70S-78S, 2004.
56. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Cambell PW. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA 290: 1749-1756, 2003.
57. Sampson AP. The role of eosinophils and neutrophils in inflammation. Clin Exp Allergy 30: 22-27, 2000.
58. Schulz C, Farkas L, Wolf K, Kratzel K, Eissner G, Pfeifer M. Differences in LPS-induced activation of bronchial epithelial cells (BEAS-2B) and type II-like pneumocytes (A-549). Scand J Immunol 56: 294-302, 2002.
59. Shapiro L, Dinarello CA. Osmotic regulation of cytokine synthesis in vitro. Proc Natl Acad Sci USA 92: 12230-12234, 1995.
60. Shimizu T, Kida Y, Kuwano K. Triacylated lipoproteins derived from Mycoplasma pneumoniae activate nuclear factor-κB through toll-like receptors 1 and 2. Immunology 121: 473-483, 2007.
61. Simecka JW. Immune responses following mycoplasma infection. In: Mycoplasmas: Molecular Biology, Pathogenicity, and Strategies for Control, edited by Blanchard A and Browning G. Norfolk, U. K.: Horizon Bioscience, 2005, p. 485-534.
62. Singh AM, Busse WW. Asthma exacerbations: Aetiology. Thorax 61: 809-816, 2006.
63. Smith PF. Membrane lipid and lipopolysaccharide structures. In: Mycoplasmas: Molecular Biology and Pathogenesis, edited by Maniloff J, McElhaney RN, Finch LR, and Baseman JB. Washington, D.C.: American Society for Microbiology, 1992, p. 79-91.
64. Sohn MH, Lee KE, Choi SY, Kwon BC, Chang MW, Kim KE. Effect of Mycoplasma pneumoniae lysate on interleukin-8 gene expression in human respiratory epithelial cells. Chest 128: 322-326, 2005.
65. 61a.Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P, Herrlich P. Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 12: 3879-3891, 1993.
66. Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 8: 459-463, 2002.
67. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, Tanaka M, Kasama T, Kobayashi K, Nakajima J, Ito K. Erthromycin modulates IL-8 expression in normal and inflammed human bronchial epithelial cells. Am J Respir Crit Care Med 156: 266-271, 1997.
68. Takizawa H, Desaki M, Ohtoshi T, Kitamura T, Okazaki H, Sato M, Akiyama N, Shoji S, Hiramatsu K, Ito K. Erythromycin suppresses interleukin 6 expression by human bronchial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 210: 781-786, 1995.
69. Tanimoto Y, Takahashi K, Kimura I. Effects of cytokines on human basophil chemotaxis. Clin Exp Allergy 22: 1020-1025, 1992.
70. Webster AD, Furr PM, Hughes-Jones NC, Gorick BD, and Taylor-Robinson D. Critical dependence on antibody for defence against mycoplasmas. Clin Exp Immunol 71: 383-387, 1988.
71. Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A, Fabian I. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-κB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother 48: 1974-1982, 2004.
72. Werber S, Shalit I, Fabian I, Steuer G, Weiss T, Blau H. Moxifloxacin inhibits cytokine-induced MAP kinase and NK-κB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. J Antimicrob Chemother 55: 293-300, 2005.
73. Wieslander A, Boyer MJ, Wroblewski H. Membrane protein structure. In: Mycoplasmas: Molecular Biology and Pathogenesis, edited by Maniloff J, McElhaney RN, Finch LR, and Baseman JB. Washington, D. C.: American Society for Microbiology, 1992, p. 93-112.
74. Winston BW, Chan ED, Johnson GL, Riches DWH. Activation of p38mapk, MKK3, and MKK4 by TNF-α in mouse bone marrow-derived macrophages. J Immunol 159: 4491-4497, 1997.
75. Winterbourn CC. Biological reactivity and biomarkers of the neutrophil oxidant, hypochlorous acid. Toxicology 181-182: 223-227, 2002.
76. Woodruff PG, Fahy JV. A role for neutrophils in asthma? Am J Med 112: 498-500, 2002.
77. Wu GD, Lai EJ, Huang N, Wen X. Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin-8 promoter. J Biol Chem 272: 2396-2403, 1997.
78. Wu Q, Martin RJ, Lafasto S, Efaw BJ, Rino JG, Harbeck RJ, Chu HW. Toll-like receptor 2 down-regulation in established mouse allergic lungs contributes to decreased mycoplasma clearance. Am J Respir Crit Care Med 177: 720-729, 2008.
79. Yang J, Hooper WC, Phillips DJ, Talkington DF. Regulation of proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae. Infect Immun 70: 3649-3655, 2002.
80. 2-terminal kinase regulation but does not cause a measurable defect in NF-κB activation. Proc Natl Acad Sci USA 97: 7272-7277, 2000.
81. Zalewska-Kaszubska J, Gorska D. Anti-inflammatory capabilities of macrolides. Pharmacol Res 44: 451-454, 2001.